MONTE E MARTIN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- CAMPBELLSVILLE, KY
- NPI
- 1821138686
- Received
- $14,683 in 775 records, 2019 to 2025
- As principal investigator
- $1,685 of research payments to others in 31 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 123 | $2,644 |
| 2024 | General payment | 121 | $2,604 |
| 2023 | General payment | 100 | $2,102 |
| 2022 | General payment | 117 | $2,160 |
| 2021 | General payment | 83 | $1,447 |
| 2020 | General payment | 73 | $1,127 |
| 2019 | General payment | 158 | $2,596 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Food and Beverage | 768 | $14,360 |
| Education | 7 | $322 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-12-11 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-10 | PUMA BIOTECHNOLOGY, INC. | $21 | Food and Beverage | In-kind items and services | NERLYNX Drug, ONCOLOGY | 2025 | |
| 2025-12-08 | Astellas Pharma US Inc | $14 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2025 | |
| 2025-12-04 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-11-25 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-11-13 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-11-11 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-11-10 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-11-06 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-11-05 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-11-04 | Takeda Pharmaceuticals U.S.A., Inc. | $39 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-10-31 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-10-30 | Ipsen Biopharmaceuticals, Inc | $30 | Food and Beverage | In-kind items and services | Onivyde Drug, Oncology | 2025 | |
| 2025-10-29 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-21 | Incyte Corporation | $26 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-10-20 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-10-15 | Janssen Biotech, Inc. | $18 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-10-14 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-10-09 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-10-08 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-10-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | $32 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-06 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-10-01 | Caris MPI, Inc. | $17 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-09-30 | Alexion Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-09-29 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2025 | |
| 2025-09-25 | Genentech USA, Inc. | $26 | Food and Beverage | In-kind items and services | Tecentriq Biological, BioOncology | 2025 | |
| 2025-09-24 | JAZZ PHARMACEUTICALS INC. | $30 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-09-22 | Genentech USA, Inc. | $18 | Food and Beverage | In-kind items and services | Polivy Biological, BioOncology | 2025 | |
| 2025-09-15 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-09-10 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-09-09 | Genmab U.S., Inc. | $21 | Food and Beverage | In-kind items and services | Tivdak Drug, Oncology | 2025 | |
| 2025-09-08 | E.R. Squibb & Sons, L.L.C. | $27 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-09-03 | SEAGEN INC. | $95 | Education | In-kind items and services | 2025 | ||
| 2025-08-28 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-27 | Celgene Corporation | $33 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-21 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2025 | |
| 2025-08-20 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-08-18 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-08-18 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-08-14 | Agios Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-08-13 | ARRAY BIOPHARMA INC | $18 | Food and Beverage | In-kind items and services | XALKORI Drug, ONCOLOGY | 2025 | |
| 2025-08-11 | Caris MPI, Inc. | $15 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-08-06 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-08-05 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2025 | |
| 2025-07-31 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-07-31 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-07-30 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-07-30 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-07-28 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-07-24 | Astellas Pharma US Inc | $13 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2025 | |
| 2025-07-23 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-07-22 | GlaxoSmithKline, LLC. | $23 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-07-21 | BeOne Medicines USA, Inc. | $23 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-07-17 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-07-16 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-15 | Janssen Biotech, Inc. | $18 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-07-15 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-07-14 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-07-09 | Celgene Corporation | $24 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-07-08 | ARRAY BIOPHARMA INC | $8 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2025-07-02 | Takeda Pharmaceuticals U.S.A., Inc. | $37 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-07-01 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-06-26 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-06-25 | Genmab U.S., Inc. | $16 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-06-23 | Blueprint Medicines Corporation | $20 | Food and Beverage | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2025 | |
| 2025-06-19 | Gilead Sciences, Inc. | $20 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-06-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-11 | Eisai Inc. | $17 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2025 | |
| 2025-06-09 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-06-04 | Novartis Pharmaceuticals Corporation | $31 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-06-04 | Genentech USA, Inc. | $27 | Food and Beverage | In-kind items and services | Lunsumio Biological, BioOncology | 2025 | |
| 2025-06-02 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2025 | |
| 2025-05-27 | Gilead Sciences, Inc. | $19 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-05-22 | RECORDATI_RARE_DISEASES_INC. | $20 | Food and Beverage | In-kind items and services | ENJAYMO Drug, HEMATOLOGY | 2025 | |
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-19 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-05-15 | Takeda Pharmaceuticals U.S.A., Inc. | $16 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2025 | |
| 2025-05-14 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-05-08 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-05-07 | Janssen Biotech, Inc. | $23 | Food and Beverage | In-kind items and services | TALVEY Biological, Oncology | 2025 | |
| 2025-05-05 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2025 | |
| 2025-04-30 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-04-29 | Merck Sharp & Dohme LLC | $22 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-04-28 | PharmaEssentia USA Corporation | $23 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-04-10 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-04-10 | AstraZeneca Pharmaceuticals LP | $3 | Food and Beverage (5 payments) | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-04-09 | BeOne Medicines USA, Inc. | $18 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-04-08 | Incyte Corporation | $28 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-04-07 | PFIZER INC. | $25 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-04-02 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2025 | |
| 2025-04-01 | Celgene Corporation | $21 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-03-31 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-03-25 | Ipsen Biopharmaceuticals, Inc | $24 | Food and Beverage | In-kind items and services | Onivyde Drug, Oncology | 2025 | |
| 2025-03-25 | Janssen Biotech, Inc. | $18 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-03-20 | Incyte Corporation | $25 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-03-20 | Incyte Corporation | $0 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-03-18 | SpringWorks Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | OGSIVEO Drug, DESMOID TUMORS | 2025 | |
| 2025-03-17 | GlaxoSmithKline, LLC. | $22 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-03-14 | Celltrion USA Inc. | $19 | Food and Beverage | In-kind items and services | VEGZELMA Biological, ONCOLOGY | 2025 | |
| 2025-03-12 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-10 | Genmab U.S., Inc. | $21 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-02-26 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-24 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-02-17 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-02-12 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-02-10 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-02-03 | Janssen Biotech, Inc. | $25 | Food and Beverage | In-kind items and services | TALVEY Biological, Oncology | 2025 | |
| 2025-01-30 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-01-29 | Regeneron Healthcare Solutions, Inc. | $26 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-01-29 | Blue Earth Diagnostics | $17 | Food and Beverage | In-kind items and services | POSLUMA Drug, Diagnostic Imaging | 2025 | |
| 2025-01-24 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-01-23 | Aveo Pharmaceuticals, Inc. | $20 | Education | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-01-23 | Aveo Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-01-22 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-01-22 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2025 | |
| 2025-01-21 | Astellas Pharma US Inc | $16 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-01-17 | Janssen Biotech, Inc. | $23 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-01-16 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-01-15 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-01-13 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2025 | |
| 2025-01-08 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2025 | |
| 2024-12-20 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2024 | |
| 2024-12-19 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2024 | |
| 2024-12-16 | GENZYME CORPORATION | $17 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2024 | |
| 2024-12-11 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-12-06 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-12-05 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2024 | |
| 2024-12-03 | Secura Bio, Inc. | $18 | Food and Beverage | In-kind items and services | COPIKTRA Drug, ORAL ONCOLOGIC | 2024 | |
| 2024-12-02 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2024 | |
| 2024-12-01 | Coherus Oncology, Inc. | $29 | Food and Beverage | In-kind items and services | Udenyca Biological, Granulocyte colony stimulating factor | 2024 | |
| 2024-11-25 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2024 | |
| 2024-11-21 | Merck Sharp & Dohme LLC | $25 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-19 | Merck Sharp & Dohme LLC | $17 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-18 | SOBI, INC | $22 | Food and Beverage | In-kind items and services | VONJO Drug, HEMATOLOGY/ONCOLOGY | 2024 | |
| 2024-11-13 | Astellas Pharma US Inc | $23 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2024 | |
| 2024-11-07 | Mirati Therapeutics, Inc. | $18 | Food and Beverage | Cash or cash equivalent | KRAZATI Drug, Oncology | 2024 | |
| 2024-11-06 | Tempus AI, Inc | $29 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-05 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-11-04 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-11-01 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2024 | |
| 2024-10-31 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2024 | |
| 2024-10-30 | Daiichi Sankyo Inc. | $26 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-10-30 | Genentech USA, Inc. | $18 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2024 | |
| 2024-10-29 | Daiichi Sankyo Inc. | $27 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-10-29 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-10-24 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2024 | |
| 2024-10-19 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2024 | |
| 2024-10-18 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Itovebi Biological, BioOncology | 2024 | |
| 2024-10-17 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-10-16 | Pharmacosmos Therapeutics Inc. | $21 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-10-16 | KYOWA KIRIN, INC. | $15 | Food and Beverage | In-kind items and services | Poteligeo Drug, Monoclonal Antibody | 2024 | |
| 2024-10-15 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2024 | |
| 2024-10-14 | Gilead Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-09 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-08 | SpringWorks Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | OGSIVEO Drug, DESMOID TUMORS | 2024 | |
| 2024-10-04 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-10-02 | Pharmacosmos Therapeutics Inc. | $17 | Food and Beverage | In-kind items and services | COSELA Drug, HEMATOLOGY | 2024 | |
| 2024-10-01 | Cumberland Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | SANCUSO Drug, ONCOLOGY | 2024 | |
| 2024-09-27 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2024 | |
| 2024-09-25 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2024 | |
| 2024-09-24 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-09-23 | Daiichi Sankyo Inc. | $28 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-09-20 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-09-19 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2024 | |
| 2024-09-18 | Daiichi Sankyo Inc. | $28 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-09-12 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-09-11 | Celgene Corporation | $24 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-09-10 | Daiichi Sankyo Inc. | $22 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-09-06 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-09-04 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-09-03 | Daiichi Sankyo Inc. | $27 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2024 | |
| 2024-09-03 | Pharmacosmos Therapeutics Inc. | $19 | Food and Beverage | In-kind items and services | COSELA Drug, HEMATOLOGY | 2024 | |
| 2024-08-30 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2024 | |
| 2024-08-29 | Janssen Biotech, Inc. | $26 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2024 | |
| 2024-08-28 | Takeda Pharmaceuticals U.S.A., Inc. | $29 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2024 | |
| 2024-08-26 | Incyte Corporation | $21 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2024 | |
| 2024-08-23 | Janssen Biotech, Inc. | $15 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2024 | |
| 2024-08-22 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-08-21 | Celgene Corporation | $22 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-08-21 | Gilead Sciences, Inc. | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-19 | GlaxoSmithKline, LLC. | $24 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2024 | |
| 2024-08-16 | Novartis Pharmaceuticals Corporation | $10 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-08-15 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | In-kind items and services | Odomzo Drug, Oncology | 2024 | |
| 2024-08-15 | Mirati Therapeutics, Inc. | $15 | Food and Beverage | Cash or cash equivalent | KRAZATI Drug, Oncology | 2024 | |
| 2024-08-13 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2024 | |
| 2024-08-12 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2024 | |
| 2024-08-09 | Janssen Biotech, Inc. | $14 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2024 | |
| 2024-08-08 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2024 | |
| 2024-08-07 | Regeneron Healthcare Solutions, Inc. | $30 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-08-06 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2024 | |
| 2024-07-31 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2024 | |
| 2024-07-30 | Eisai Inc. | $21 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2024-07-29 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-07-26 | Daiichi Sankyo Inc. | $23 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-07-25 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2024 | |
| 2024-07-24 | Pharmacosmos Therapeutics Inc. | $18 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2024 | |
| 2024-07-23 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2024 |
The latest 200 records of 775.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2020-11-24 | Merck Sharp & Dohme LLC | CORA NCORP | $100 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | CORA NCORP | $100 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | CORA NCORP | $100 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | CORA NCORP | $100 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | CORA NCORP | $50 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-22 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-22 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-06-16 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-06-16 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-03-25 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-03-25 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-03-24 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-03-24 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-02-12 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-02-12 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-01-02 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-01-02 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2019-11-21 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-10-21 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | CORA NCORP | $50 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | CORA NCORP | $41 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-08-28 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-08-28 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-08-17 | Merck Sharp & Dohme LLC | FLAGET CANCER CENTER RESEARCH | $32 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | CORA NCORP | $60 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | CORA NCORP | $50 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | CORA NCORP | $30 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-07 | Merck Sharp & Dohme LLC | CORA NCORP | $100 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-05 | Merck Sharp & Dohme LLC | CORA NCORP | $50 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-03-05 | Merck Sharp & Dohme LLC | CORA NCORP | $41 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Campbellsville, KY, county Taylor County, KY, state Kentucky; placed by its city name.
| Measure | Place (city or town) Campbellsville, KY | County Taylor County, KY | State Kentucky |
|---|---|---|---|
| Population B01003 | 11,622 | 26,397 | 4,534,824 |
| Population, 2020 census P1 | 11,426 | 26,023 | 4,505,836 |
| Median age B01002 | 37.2 | 37.8 | 39.1 |
| Under 18 B01001 | 21.1% | 23.0% | 22.6% |
| 65 and over B01001 | 19.4% | 18.2% | 17.3% |
| Households B11001 | 4,863 | 10,260 | 1,814,469 |
| Foreign born B05002 | 2.6% | 1.3% | 4.7% |
| Median household income B19013 | $49,644 | $60,456 | $63,726 |
| Median family income B19113 | $68,060 | $81,452 | $81,505 |
| Per capita income B19301 | $26,211 | $28,896 | $35,821 |
| Poverty rate B17001 | 23.4% | 17.5% | 16.1% |
| Unemployment rate B23025 | 7.4% | 5.1% | 4.9% |
| Civilian labor force B23025 | 5,331 | 12,599 | 2,152,038 |
| Mean commute (minutes) B08013 | 16.6 | 22.7 | 24.0 |
| Bachelor's degree or higher B15003 | 24.7% | 23.0% | 27.6% |
| Housing units B25001 | 5,057 | 11,210 | 2,023,116 |
| Owner-occupied B25003 | 48.6% | 68.8% | 68.3% |
| Renters B25003 | 51.4% | 31.2% | 31.7% |
| Median home value B25077 | $164,600 | $174,200 | $205,600 |
| Median gross rent B25064 | $685 | $718 | $967 |
| White, not Hispanic B03002 | 81.1% | 87.7% | 81.5% |
| Black B03002 | 9.7% | 4.6% | 7.6% |
| Hispanic or Latino B03002 | 2.9% | 3.1% | 5.0% |
| Asian B03002 | 0.9% | 1.0% | 1.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Campbellsville, KY.
Comments